DYRK2 controls a key regulatory network in chronic myeloid leukemia stem cells
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
DYRK2 controls a key regulatory network in chronic myeloid leukemia stem cells
Authors
Keywords
-
Journal
EXPERIMENTAL AND MOLECULAR MEDICINE
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-10-16
DOI
10.1038/s12276-020-00515-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prostaglandin E2 confers protection against diabetic coronary atherosclerosis by stimulating M2 macrophage polarization via the activation of the CREB/BDNF/TrkB signaling pathway
- (2020) Changlong Bi et al. FASEB JOURNAL
- Vitamin K-antagonism impairs the bone marrow microenvironment and hematopoiesis
- (2019) Divij Verma et al. BLOOD
- Chronic myeloid leukemia stem cells
- (2019) Mohammad Houshmand et al. LEUKEMIA
- Forced expression of DYRK2 exerts anti-tumor effects via apoptotic induction in liver cancer
- (2019) Shiho Yokoyama-Mashima et al. CANCER LETTERS
- Combined inhibition of MDM2 and Bcr-Abl tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model
- (2019) Bing Z. Carter et al. HAEMATOLOGICA
- KLF4 Represses DYRK2 Inhibition of Self-renewal and Survival Through c-Myc and p53 in Leukemia Stem/Progenitor Cells
- (2019) Chun Shik Park et al. BLOOD
- Multiple functions of DYRK2 in cancer and tissue development
- (2019) Saishu Yoshida et al. FEBS LETTERS
- Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia
- (2019) Fabien Muselli et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression
- (2019) Sourav Banerjee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States
- (2019) Taisen Hao et al. Scientific Reports
- Sequential phosphorylation of NDEL1 by the DYRK2-GSK3β complex is critical for neuronal morphogenesis
- (2019) Youngsik Woo et al. eLife
- Harmine, a dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor induces caspase-mediated apoptosis in neuroblastoma
- (2018) Katie L. Uhl et al. Cancer Cell International
- Downregulation of dual-specificity tyrosine-regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin-dependent kinase 14 expression in breast cancer
- (2018) Yoshimi Imawari et al. CANCER SCIENCE
- Dyrk2 mediated the release of proinflammatory cytokines in LPS-induced BV2 cells
- (2018) Li Xu et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2
- (2018) Sourav Banerjee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL + human leukemia
- (2018) Damian Lai et al. Science Translational Medicine
- Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial
- (2018) Maro Ohanian et al. Lancet Haematology
- Targeting the Extracellular Signal-Regulated Kinase 5 Pathway to Suppress Human Chronic Myeloid Leukemia Stem Cells
- (2018) Ignazia Tusa et al. Stem Cell Reports
- DYRK2 displays muscle fiber type specific function during zebrafish early somitogenesis
- (2017) Wei Sun et al. INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY
- Dual-specificity tyrosine phosphorylation-regulated kinase 2 regulates osteoclast fusion in a cell heterotypic manner
- (2017) Gali Guterman-Ram et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia
- (2017) Gabriel Etienne et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells
- (2017) Elodie M Kuntz et al. NATURE MEDICINE
- Regulation of Glioma Cells Migration by DYRK2
- (2017) Yifen Shen et al. NEUROCHEMICAL RESEARCH
- Discontinuation of TKI therapy and ‘functional’ cure for CML
- (2016) François-Xavier Mahon BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function
- (2016) Meifang Xiao et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche
- (2016) Haobin Ye et al. Cell Stem Cell
- Hematopoietic and Leukemic Stem Cells Have Distinct Dependence on Tcf1 and Lef1 Transcription Factors
- (2016) Shuyang Yu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia
- (2016) W Huang et al. LEUKEMIA
- Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells
- (2016) Sheela A. Abraham et al. NATURE
- Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer
- (2016) R Mimoto et al. ONCOGENE
- Downregulated DYRK2 expression is associated with poor prognosis and Oxaliplatin resistance in hepatocellular carcinoma
- (2016) Xiubing Zhang et al. PATHOLOGY RESEARCH AND PRACTICE
- Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells
- (2016) Bing Z. Carter et al. Science Translational Medicine
- Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition
- (2016) M. T. Scott et al. Cancer Discovery
- Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia
- (2016) David A. Irvine et al. Scientific Reports
- Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer
- (2016) Haiyan Yan et al. PLoS One
- LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential
- (2015) Christopher S Hong et al. CANCER BIOLOGY & THERAPY
- Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis
- (2015) Xing Guo et al. NATURE CELL BIOLOGY
- Tyrosine kinase inhibitor–induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling
- (2015) Carsten Riether et al. Science Translational Medicine
- DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma
- (2015) Noriko Yamaguchi et al. TUMOR BIOLOGY
- Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells
- (2015) Bing Z. Carter et al. Oncotarget
- DYRK2 Negatively Regulates Type I Interferon Induction by Promoting TBK1 Degradation via Ser527 Phosphorylation
- (2015) Tai An et al. PLoS Pathogens
- Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells
- (2015) Hanyang Lin et al. Oncotarget
- Stability of the human pregnane X receptor is regulated by E3 ligase UBR5 and serine/threonine kinase DYRK2
- (2014) Su Sien Ong et al. BIOCHEMICAL JOURNAL
- JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo
- (2014) P. Gallipoli et al. BLOOD
- Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition
- (2014) K. P. Ng et al. BLOOD
- Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival
- (2014) Yaoyu Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia
- (2014) A M Eiring et al. LEUKEMIA
- A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia
- (2014) J F Seymour et al. Blood Cancer Journal
- Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt- -catenin signaling
- (2013) B. Zhang et al. BLOOD
- Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
- (2013) D. M. Ross et al. BLOOD
- Regulation of c-Myc Ubiquitination Controls Chronic Myelogenous Leukemia Initiation and Progression
- (2013) Linsey Reavie et al. CANCER CELL
- DYRK2 controls the epithelial–mesenchymal transition in breast cancer by degrading Snail
- (2013) Rei Mimoto et al. CANCER LETTERS
- A Pan-BCL2 Inhibitor Renders Bone-Marrow-Resident Human Leukemia Stem Cells Sensitive to Tyrosine Kinase Inhibition
- (2013) Daniel J. Goff et al. Cell Stem Cell
- Targeting of the signal transducer Smo links microRNA-326 to the oncogenic Hedgehog pathway in CD34+CML stem/progenitor cells
- (2013) Sadegh Babashah et al. INTERNATIONAL JOURNAL OF CANCER
- Dyrk2-associated EDD-DDB1-VprBP E3 Ligase Inhibits Telomerase by TERT Degradation
- (2013) Hae-Yun Jung et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells
- (2013) Paolo Neviani et al. JOURNAL OF CLINICAL INVESTIGATION
- Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
- (2013) Philippe Rousselot et al. JOURNAL OF CLINICAL ONCOLOGY
- Drosophila Dyrk2 Plays a Role in the Development of the Visual System
- (2013) Nathan Luebbering et al. PLoS One
- PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor
- (2013) K Airiau et al. Cell Death & Disease
- HIF1 is required for survival maintenance of chronic myeloid leukemia stem cells
- (2012) H. Zhang et al. BLOOD
- Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib
- (2012) Ling Li et al. CANCER CELL
- Dpysl2 (CRMP2) and Dpysl3 (CRMP4) phosphorylation by Cdk5 and DYRK2 is required for proper positioning of Rohon-Beard neurons and neural crest cells during neurulation in zebrafish
- (2012) Hideomi Tanaka et al. DEVELOPMENTAL BIOLOGY
- DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells
- (2012) Naoe Taira et al. JOURNAL OF CLINICAL INVESTIGATION
- MK-0457, an Aurora kinase and BCR–ABL inhibitor, is active in patients with BCR–ABL T315I leukemia
- (2012) F J Giles et al. LEUKEMIA
- The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells
- (2012) Haojian Zhang et al. NATURE GENETICS
- SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells
- (2012) Z Wang et al. ONCOGENE
- Mutual regulation between SIAH2 and DYRK2 controls hypoxic and genotoxic signaling pathways
- (2012) Moisés Pérez et al. Journal of Molecular Cell Biology
- Curing Chronic Myeloid Leukemia
- (2012) Delphine Rea et al. Current Hematologic Malignancy Reports
- Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis
- (2011) H. Yuan et al. BLOOD
- Identification of DNA methylation changes associated with human gastric cancer
- (2011) Jung-Hoon Park et al. BMC Medical Genomics
- The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells
- (2011) F Pellicano et al. LEUKEMIA
- Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors
- (2011) E Traer et al. LEUKEMIA
- Targeted therapy of chronic myeloid leukemia
- (2010) Con Sullivan et al. BIOCHEMICAL PHARMACOLOGY
- Wnt/Ca2+/NFAT Signaling Maintains Survival of Ph+ Leukemia Cells upon Inhibition of Bcr-Abl
- (2010) Mark A. Gregory et al. CANCER CELL
- Targeting of Leukemia-Initiating Cells to Develop Curative Drug Therapies: Straightforward but Nontrivial Concept
- (2010) P. Valent CURRENT CANCER DRUG TARGETS
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemia
- (2010) A Samanta et al. LEUKEMIA
- Inhibition of Grb2 expression demonstrates an important role in BCR–ABL-mediated MAPK activation and transformation of primary human hematopoietic cells
- (2010) H Modi et al. LEUKEMIA
- TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
- (2010) Kazuhito Naka et al. NATURE
- Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
- (2009) Chen Zhao et al. NATURE
- Protein kinase DYRK2 is a scaffold that facilitates assembly of an E3 ligase
- (2009) Subbareddy Maddika et al. NATURE CELL BIOLOGY
- Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia
- (2009) Yaoyu Chen et al. NATURE GENETICS
- Polo kinases regulate C. elegans embryonic polarity via binding to DYRK2-primed MEX-5 and MEX-6
- (2008) Y. Nishi et al. DEVELOPMENT
- Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy
- (2008) J A McCubrey et al. LEUKEMIA
- PML targeting eradicates quiescent leukaemia-initiating cells
- (2008) Keisuke Ito et al. NATURE
- FOXOs, cancer and regulation of apoptosis
- (2008) Z Fu et al. ONCOGENE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started